ANAVEON AG
@anaveon.com
ANAVEON - Autoimmunity Autoimmune disease Inflammation Systemic autoimmune disorder Chronic inflammation T cell–mediated autoimmunity PD1/PD-1 PD-1 agonism T cell depletion T cell modulation Immune checkpoint modulation Disease-modifying therapy Rheumatic disease Sjögren's disease Sjögren's syndrome Rheumatoid Arthritis Giant cell arteritis Lupus Best-in-class ADCC
ANAVEON AG's Company Logos
ANAVEON AG's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FF1E00
Scarlet
255, 30, 0
7, 100, 50
0, 88, 100, 0
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#334266
Rhino
51, 66, 102
222, 33, 30
50, 35, 0, 60
About ANAVEON AG
Anaveon is a clinical stage company that specializes in transforming immunological insights into life-saving therapies. Their mission is to design and develop cutting-edge treatments that benefit both patients and society. With a dedicated team of expert scientists who have decades of experience in drug development, Anaveon is at the forefront of developing safe and effective treatments using the power of cytokines.
Their lead compound, ANV419, is a selective interleukin-2 (IL-2) receptor agonist that has shown promising results in promoting the function of immune effector cells. This makes it a potential treatment for various types of cancer. Anaveon is also working on a pipeline of targeted cytokines to treat a range of diseases, further leveraging their expertise and state-of-the-art facilities.
Led by Co-Founder and CEO Andreas Katopodis, the team at Anaveon is committed to following novel approaches with clear scientific rationale to reach their shared vision. They are actively seeking partnerships and funding to strengthen their programs and continue developing tomorrow's treatments. Contact Anaveon today to learn more about their groundbreaking science and clinical activities
Company type
Privately Held
Year founded
2017
Company size
11-50 employees
